Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is N/A as of Tuesday, October 6, 2026.
GROSS MARGIN
N/A
Market Cap
$206.19M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$208.37M
Gross Margin
83.89%
TTM Avg
91.94%
3Y Avg
70.97%
5Y Avg
47.31%
Market Cap
$203.92M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
99.54%
5Y Avg
99.69%
Market Cap
$211.79M
Gross Margin
85.91%
TTM Avg
92.95%
3Y Avg
46.48%
5Y Avg
30.98%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Electra Therapeutics Inc. (ETRA) | $206.82M | N/A | N/A | N/A | N/A |
| Sionna Therapeutics, Inc. (SION)vs › | $206.19M | 0.00% | 0.00% | 0.00% | 0.00% |
| Alector, Inc. (ALEC)vs › | $204.37M | 54.09% | -15.41% | 40.02% | -79.15% |
| Entrada Therapeutics, Inc. (TRDA)vs › | $208.37M | 83.89% | 91.94% | 70.97% | 47.31% |
| Pro-Dex, Inc. (PDEX)vs › | $208.71M | 31.38% | 30.34% | 28.84% | 29.64% |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $203.92M | 100.00% | 100.00% | 99.54% | 99.69% |
| Compugen Ltd. (CGEN)vs › | $211.80M | 86.89% | 79.42% | 84.96% | 87.58% |
| Surrozen, Inc. (SRZN)vs › | $202.26M | 84.56% | 92.28% | 64.60% | 43.07% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $211.79M | 85.91% | 92.95% | 46.48% | 30.98% |
| Exagen Inc. (XGN)vs › | $200.00M | 58.64% | 58.89% | 55.18% | 56.44% |
Gross Margin
N/A
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
